![Radiotherapy](/sites/default/files/styles/card/public/2024-04/Image%20for%20talk.png?h=f5c7b304&itok=R_R49m4n)
Precision targeted radiotherapy for cancer: current and future paradigms
Dr. Billy W. Loo, Stanford
Abstract: Radiation therapy has become one of the most effective and cost effective precision targeted cancer therapies. This colloquium
will review the evolution of radiotherapy in recent years, and highlight future directions in its continued evolution towards more
effective cure of cancer.
About Dr. Billy W. Loo
![Billy Loo Headshot](/sites/default/files/styles/medium/public/2024-04/Billy%20Loo%20Headshot.jpg?itok=UGs9iUXR)
Billy W. Loo Jr., MD PhD is a Professor of Radiation Oncology, a member of the Stanford Cancer Institute, of the Molecular Imaging Program at Stanford (MIPS), and of Bio-X. He is a physician-scientist Radiation Oncologist and Bioengineer who directs the Thoracic Radiation Oncology Program and is Principal Investigator of the FLASH Sciences Lab @Stanford. His clinical specialty is state-of-the-art precision radiotherapy for lung/thoracic cancers, including stereotactic ablative radiotherapy (SABR). Dr. Loo is a recognized expert in thoracic cancers serving on multiple national committees (including as writing member or vice-chair) that publish clinical guidelines on the treatment of lung cancer and other thoracic malignancies, particularly the National Comprehensive Cancer Network (NCCN).
Audience: